"10.1371_journal.pone.0122589","plos one","2015-03-31T00:00:00Z","Marc Y R Henrion; Mark P Purdue; Ghislaine Scelo; Peter Broderick; Matthew Frampton; Alastair Ritchie; Angela Meade; Peng Li; James McKay; Mattias Johansson; Mark Lathrop; James Larkin; Nathaniel Rothman; Zhaoming Wang; Wong-Ho Chow; Victoria L Stevens; W Ryan Diver; Demetrius Albanes; Jarmo Virtamo; Paul Brennan; Timothy Eisen; Stephen Chanock; Richard S Houlston","Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom; Division of Cancer Epidemiology and Genetics, Department Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America; Division of Cancer Prevention and Population Sciences, Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America; MRC Clinical Trials Unit at University College London, Aviation House, London, United Kingdom; Royal Marsden NHS Foundation Trust, London, United Kingdom; Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc., Gaithersburg, Maryland, United States of America; Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, United States of America; Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland; Cambridge University Health Partners, Cambridge, United Kingdom; International Agency for Research on Cancer, Lyon, France; McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada","Conceived and designed the experiments: RSH SC P. Brennan MPP. Performed the experiments: AR AM PL JM MJ ML JL NR ZW WHC VLS WRD DA JV TE. Analyzed the data: MYRH MPP GS MF. Wrote the paper: MYRH RSH MPP GS P. Broderick SC.","Zhaoming Wang is employed by Leidos Biomedical Research Inc., a US government contractor. Timothy Eisen is Chief Investigator of SORCE and has received research support form Bayer, GlaxoSmithKline, Pfizer and AstraZeneca, has taken part and been compensated for advisory boards for GlaxoSmithKline, Aveo and Astellas and is currently on leave of absence from the University of Cambridge to work as Chief Clinician Scientist at AstraZeneca. SORCE, though coordinated by the Medical Research Council (MRC) Clinical Trials Unit (CTU) at UCL and funded principally by the MRC CTU at UCL and Cancer Research UK, has been funded partially by an educational grant from a commercial source, Bayer. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.","2015","03","Marc Y R Henrion","MYRH",23,TRUE,3,15,4,5,TRUE,TRUE,FALSE,0,NA,FALSE
